Ligand Pharmaceuticals stock (US53220K1060): BofA lifts price target as shares trade near mid-230s on Nasdaq

Ligand Pharmaceuticals shares on the Nasdaq in the United States traded in the mid-USD 230s after BofA Securities nudged its price target to USD 266 on 05/28/2026, underscoring ongoing interest in the biopharma royalty specialist.

Ligand Pharmaceuticals shares on the Nasdaq in the United States were recently quoted around the mid-USD 230s after BofA Securities increased its price target for the stock to USD 266 on 05/28/2026, according to MT Newswires citing a research note from the bank.MarketScreener/MT Newswires as of 05/28/2026

The move by the US-based investment bank provides a fresh trading reference point for investors following the stock’s development on its home exchange and comes as Ligand Pharmaceuticals continues to generate revenue primarily through royalties and milestone payments from partnered therapies.Ligand investor relations as of 03/06/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Ligand Pharmaceuticals
• Sector/industry: Biopharmaceutical royalties and drug development technologies
• Headquarters/country: San Diego, United States
• Core markets: United States and international biopharma partners
• Key revenue drivers: Royalties, contract payments, and milestone revenues from partnered therapeutics and licensing of technology platforms
• Home exchange/listing venue: Nasdaq (LGND)
• Trading currency: USD

Ligand Pharmaceuticals: core business model

Ligand Pharmaceuticals focuses on building a portfolio of partnered medicines and licensing-ready technologies, earning most of its revenue from royalties, contract payments, and milestone fees tied to the commercial success of drugs developed by its collaboration partners.Ligand Q1 2026 release as of 05/08/2026

Valuation metrics and multiples for Ligand Pharmaceuticals

Valuation of Ligand Pharmaceuticals is typically framed around the company’s portfolio of royalty streams and its technology assets, with investors looking at market capitalization relative to expected royalty cash flows and earnings from licensing activities.MarketScreener as of 05/28/2026

Data providers tracking the stock on the Nasdaq show a last close in the mid-USD 230s and an average analyst price target in the low USD 270s, which places the current share price somewhat below the mean target while leaving room for differing views on how the royalty portfolio and pipeline could contribute to future earnings and cash generation.MarketScreener consensus as of 05/28/2026

Conclusion

The latest move by BofA Securities to nudge its price target for Ligand Pharmaceuticals to USD 266 shines a spotlight on how US-based analysts value the company’s royalty streams and technology platforms relative to the current Nasdaq share price. For investors, the updated target and prevailing consensus metrics illustrate how the market weighs the prospects of Ligand Pharmaceuticals’ partnered product portfolio against the risks inherent in the biopharma sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.